During this segment, the panelists discuss treatment options for systemic lupus erythematosus (SLE) and recognize unmet treatment needs from the perspectives of the patient, provider, and payer. To improve patient outcomes, the panelists explore different ways in which treatment for SLE can be improved.
Hugh Fatodu, RPh, MBA, explains that agents currently used to treat SLE are accompanied with adverse events that affect patient adherence, and results of therapy have proven inconsistent amongst certain subgroups of patients. Therefore, clinicians currently question the ability of these agents to provide benefits to their patients.
Michelle Petri, MD, MPH, explains the ways in which long-term exposure of prednisone affects patient outcomes. Dr Petri also believes that a personalized treatment approach is necessary when treating patients.
And because long-term data is still lacking, Maria Lopes, MD, MS, believes that an early diagnosis of SLE is essential, as outcomes of severe SLE are more dangerous.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More